Oct 1, 2026 03:30AM
Sep 18, 2026 06:11AM
Sep 18, 2026 06:10AM
Aug 13, 2026 01:00AM
Aug 12, 2026 04:07PM
Aug 12, 2026 04:05PM
Jun 7, 2026 02:30PM Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in p
Jun 7, 2026 02:30PM
May 7, 2026 01:00AM
Apr 28, 2026 02:00AM
Apr 28, 2026 02:00AM
Apr 28, 2026 02:00AM
Apr 28, 2026 02:00AM
Feb 19, 2026 01:00AM Zealand Pharma Announces Financial Results for the Full Year 2025
Aug 14, 2025 01:00AM
Jun 2, 2025 01:00AM
May 19, 2025 09:00AM
Feb 20, 2025 04:08AM
Feb 20, 2025 01:00AM
Dec 19, 2024 02:59PM
Dec 19, 2024 02:58PM U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome
Nov 7, 2024 01:00AM
Oct 8, 2024 07:00PM
Oct 8, 2024 06:45PM
Oct 8, 2024 02:40AM
Aug 15, 2024 01:00AM
Jun 7, 2024 04:38AM
Jun 6, 2024 06:29AM Zealand Pharma (ZEAL) announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL
Jun 6, 2024 06:29AM
May 31, 2024 10:03AM
May 31, 2024 10:03AM
May 16, 2024 01:00AM
Feb 27, 2024 01:00AM
Feb 26, 2024 02:06AM
Dec 26, 2023 04:03AM Zealand Pharma (ZEAL) Receives CRL from FDA for dasiglucagon
Dec 23, 2023 04:47AM
Dec 22, 2023 04:30AM
Nov 9, 2023 01:00AM
Oct 5, 2023 05:53AM
Aug 30, 2023 01:33AM
Aug 17, 2023 01:00AM
Jun 30, 2023 01:34PM Zealand Pharma (ZEAL) Submits NDA for dasiglucagon
Jun 30, 2023 01:32PM
Jun 23, 2023 05:15PM
May 11, 2023 01:00AM
May 10, 2023 02:30AM
Mar 2, 2023 04:30AM
Mar 2, 2023 04:30AM
Mar 2, 2023 01:00AM Zealand Pharma Announces Full Year Results for 2022
Mar 2, 2023 01:00AM

333,461 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All